Sravnenie effektivnosti i toksichnosti rezhimov FC i FCR u pervichnykh bol'nykhV-kletochnym khronicheskim limfoleykozom
- Authors: Stadnik EA1, Nikitin EA2, Biderman BV2, Salogub GN1, Lorie Y.Y.2, Tsyba NN2, Alekseeva Y.A1, Doronin VA3, Mashchuk VN4, Vabishchevich RI5, Melikyan AL2, Kolosheynova TI2, Kolosova LY.2, Sudarikov AB2, Kovaleva LG2, Zaritskiy AY.5
-
Affiliations:
- Городская клиническая больница №31, Санкт-Петербург
- ГУ Гематологический научный центр РАМН
- ЦКБ №2 Министерства путей сообщения
- Краснодарский краевой онкодиспансер
- Федеральный центр крови, сердца и эндокринологии им. акад. В.А.Алмазова
- Issue: Vol 10, No 3 (2008)
- Pages: 60-64
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26736
- ID: 26736
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E A Stadnik
Городская клиническая больница №31, Санкт-Петербург
E A Nikitin
ГУ Гематологический научный центр РАМН
B V Biderman
ГУ Гематологический научный центр РАМН
G N Salogub
Городская клиническая больница №31, Санкт-Петербург
Yu Yu Lorie
ГУ Гематологический научный центр РАМН
N N Tsyba
ГУ Гематологический научный центр РАМН
Yu A Alekseeva
Городская клиническая больница №31, Санкт-Петербург
V A Doronin
ЦКБ №2 Министерства путей сообщения
V N Mashchuk
Краснодарский краевой онкодиспансер
R I Vabishchevich
Федеральный центр крови, сердца и эндокринологии им. акад. В.А.Алмазова
A L Melikyan
ГУ Гематологический научный центр РАМН
T I Kolosheynova
ГУ Гематологический научный центр РАМН
L Yu Kolosova
ГУ Гематологический научный центр РАМН
A B Sudarikov
ГУ Гематологический научный центр РАМН
L G Kovaleva
ГУ Гематологический научный центр РАМН
A Yu Zaritskiy
Федеральный центр крови, сердца и эндокринологии им. акад. В.А.Алмазова
References
- Catovsky D, Richards S, Matutes E et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370 (9583): 230–9.
- Eichhorst B.F., Busch R, Hopfinger G et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first - line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107 (3): 885–91.
- McLaughlin P, Grillo-Lopez A.J., Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent: Half of patients respond to a four - dose treatment program. J Clin Oncol 1998; 16: 2825–33.
- Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with Bcell chronic lymphocytic leukemia. Blood 2001; 98: 1326–31.
- Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101: 2507–13.
- O'Brien S.M., Kantarjian H, Thomas D.A. et al. Rituximab dose - escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19 (8): 2165–70.
- Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114 (4): 800–9.
- Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and rituximab. Anticancer Res 2000; 20: 2961–6.
- Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–86.
- Byrd J.C., Peterson B.L., Morrison V.A. et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101 (1): 6–14.
- Keating M.J., O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23 (18): 4079–88.
- Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23 (18): 4070–8.
- Rummel M.J., Stilgenbauer S, Gamm H et al. Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL)-preliminary results of a randomised phase-III multicenter study. Blood 2002; 100 (11): 384a, abstract 1489.
- O'Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 1993; 82: 1695–700.
- Bosch F, Perales M, Cobo F et al. Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). Blood 1997; 90 (Suppl. 1): 530a, abstract 2360.
- Tsimberidou A.M., Keating M.J., Giles F.J. et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 2004; 100 (12): 2583–91.
- Byrd J.C., Rai K, Peterson B.L. et al. Addition of rituximab to fludarabine may prolong progression - free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105 (1): 49–53.
- Никитин Е.А., Пивник А.В., Судариков А.Б. и др. Сравнение форм хронического лимфолейкоза в зависимости от мутационного статуса генов вариабельного региона иммуноглобулинов. Тер. арх. 2000; 72 (7): 52–6.
- Cheson B.D. Bennett J.M. et al. National Cancer Institute - sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–7.
- Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31–41.
- Keating M.J., O’Brien S, Lerner S et al. Long - term follow - up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–71.